Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eledon Pharmaceuticals Inc (ELDN)

Eledon Pharmaceuticals Inc (ELDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,251
  • Shares Outstanding, K 59,932
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,180 K
  • EBIT $ -86 M
  • EBITDA $ -89 M
  • 60-Month Beta 0.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.34

Options Overview Details

View History
  • Implied Volatility 231.11% (-172.16%)
  • Historical Volatility 61.81%
  • IV Percentile 36%
  • IV Rank 14.43%
  • IV High 1,025.49% on 08/11/25
  • IV Low 97.15% on 08/26/25
  • Expected Move (DTE 12) 0.40 (18.24%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 35
  • Volume Avg (30-Day) 218
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 9,276
  • Open Int (30-Day) 7,602
  • Expected Range 1.79 to 2.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.22
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +68.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.66 +31.93%
on 01/07/26
2.33 -6.01%
on 02/02/26
+0.53 (+31.93%)
since 01/06/26
3-Month
1.35 +62.22%
on 11/21/25
2.40 -8.75%
on 11/10/25
-1.91 (-46.59%)
since 11/06/25
52-Week
1.35 +62.22%
on 11/21/25
4.97 -55.89%
on 02/07/25
-2.56 (-53.89%)
since 02/06/25

Most Recent Stories

More News
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate...

ELDN : 2.19 (+11.17%)
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73...

ELDN : 2.19 (+11.17%)
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary...

ELDN : 2.19 (+11.17%)
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate...

ELDN : 2.19 (+11.17%)
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

IRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc.  (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the...

ELDN : 2.19 (+11.17%)
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus ...

ELDN : 2.19 (+11.17%)
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares...

ELDN : 2.19 (+11.17%)
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its common...

ELDN : 2.19 (+11.17%)
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m²  Tegoprubart...

ELDN : 2.19 (+11.17%)
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will present at...

ELDN : 2.19 (+11.17%)

Business Summary

Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 2.48
2nd Resistance Point 2.34
1st Resistance Point 2.26
Last Price 2.19
1st Support Level 2.05
2nd Support Level 1.91
3rd Support Level 1.83

See More

52-Week High 4.97
Fibonacci 61.8% 3.58
Fibonacci 50% 3.16
Fibonacci 38.2% 2.73
Last Price 2.19
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar